631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Beyond mutations RNA editing deaminase activation as a dynamic marker to track stem cell fitness and MPN progression

Functional characterization of a novel germline JAK2 R989fs mutation

Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms

Interleukin 12 and TNFα signaling drives parallel evolution of independent leukemic clones in JAK2V617F mutant myeloproliferative neoplasms

Selinexor alone and in combination with JAK inhibitors suppresses pro inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

Discovery of bispecific T cell engagers targeting the non mutated regions of mutant calreticulin for the treatment of myeloproliferative neoplasms

Transcriptomic analysis of CD34 cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis

Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms

The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAK inhibitor refractory resistant patients with myelofibrosis

Changes in neutrophil to lymphocyte ratio NLR in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency VAF

Identification of biomarkers to predict disease progression via molecular analysis of patients pts with low risk myelofibrosis MF enrolled in the MOST study